The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Drug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective
Abstract
Chemotherapy remains the mainstay of treatment for the lymphoma patient population, despite its relatively poor therapeutic results, high toxicity, and low specificity. With the advancement of biotechnology, the significance of drug-loading biomimetic materials in the medical field has become increasingly evident, attracting extensive attention from the scientific community and the pharmaceutical industry. Given that they can cater to the particular requirements of lymphoma patients, drug-loading biomimetic materials have recently become a potent and promising delivery approach for various applications. This review mainly reviews the recent advancements in the treatment of tumors with biological drug carrier-loaded drugs, outlines the mechanisms of lymphoma development and the diverse treatment modalities currently available, and discusses the merits and limitations of biological drug carriers. What is more, the practical application of biocarriers in tumors is explored by providing examples, and the possibility of loading such organisms with antilymphoma drugs for the treatment of lymphoma is conceived.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Protein blotting can confirm the resemblance between the surface components of the delivery system and the originating cell membrane, yet it is absent of the capability to detect possible partial membrane structure damage post-coating.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [187]
In the citing paper
“The commercialization of exosome-based vehicles faces numerous obstacles, including not fully developed preparation techniques, variable requirements, limited repeatability, and constraints in feature analysis methods.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [187]
Citations
Cites
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713976 · Cited by 940
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Research works printed but not linked: 140
- 10.1002/ajh.25856 · DOI
- 10.1016/j.canlet.2021.10.018 · DOI
- 10.1111/bjh.16575 · DOI
- 10.1016/j.pathol.2021.01.002 · DOI
- 10.1002/cncr.34483 · DOI
- 10.3322/caac.21438 · DOI
- 10.1200/JCO.18.00306 · DOI
- 10.1038/s41571-019-0184-6 · DOI
- 10.1056/NEJMoa1701769 · DOI
- 10.1016/j.ccell.2021.10.006 · DOI
- 10.1039/C5BM00186B · DOI
- 10.1021/acsnano.8b02053 · DOI
- 10.1016/j.jconrel.2021.02.016 · DOI
- 10.1021/acs.chemmater.9b00986 · DOI
- 10.1002/adma.202000416 · DOI
- 10.1016/j.jconrel.2018.11.032 · DOI
- 10.1016/j.cej.2020.125614 · DOI
- 10.1039/C7NR01097D · DOI
- 10.1021/acsnano.1c10590 · DOI
- 10.1016/j.jconrel.2023.06.014 · DOI
- 10.1002/bip.23563 · DOI
- 10.1039/D1BM01664D · DOI
- 10.1016/j.addr.2021.113974 · DOI · Paper page
- 10.3390/nano12081333 · DOI
- 10.1021/acs.langmuir.2c01556 · DOI
- 10.3322/caac.21708 · DOI · Paper page
- 10.1016/j.humpath.2019.08.019 · DOI
- 10.1038/s41571-019-0225-1 · DOI
- 10.1056/NEJMc1806191 · DOI
- 10.1038/s41591-018-0016-8 · DOI · Paper page
- 10.1038/nri3814 · DOI · Paper page
- 10.1182/blood-2017-03-769620 · DOI
- 10.1016/S0140-6736(11)61177-X · DOI
- 10.1007/s11899-015-0263-4 · DOI
- 10.1182/blood-2014-06-538504 · DOI
- 10.1002/ajh.24797 · DOI
- 10.1111/bjh.12046 · DOI
- 10.1182/blood.2020005289 · DOI
- 10.1038/nrc2230 · DOI · Paper page
- 10.1172/JCI61272 · DOI
- 10.1056/NEJMra2102568 · DOI
- 10.1182/blood.2021012386 · DOI
- 10.1016/j.beha.2016.07.005 · DOI
- 10.1182/blood-2018-11-852491 · DOI · Paper page
- 10.1056/NEJMoa1817073 · DOI
- 10.1056/NEJMe1400055 · DOI
- 10.1016/S1470-2045(18)30082-2 · DOI
- 10.1021/acsami.1c00016 · DOI
- 10.1056/NEJMoa1110557 · DOI · Paper page
- 10.3892/ijo.2014.2250 · DOI
- 10.1158/1078-0432.CCR-20-4725 · DOI
- 10.1186/s13045-015-0132-6 · DOI
- 10.1016/j.clml.2020.12.020 · DOI
- 10.1182/blood.2019001751 · DOI
- 10.1016/S0140-6736(15)01281-7 · DOI · Paper page
- 10.3109/10428194.2016.1161185 · DOI
- 10.1016/S0140-6736(22)00846-7 · DOI
- 10.3390/ijms22041877 · DOI
- 10.1016/S1470-2045(20)30441-1 · DOI
- 10.1016/j.canlet.2007.10.034 · DOI
- 10.1016/j.addr.2016.09.007 · DOI
- 10.1016/j.addr.2022.114363 · DOI
- 10.3390/biomedicines7020036 · DOI
- 10.3727/096504001108747602 · DOI
- 10.1002/adma.202106669 · DOI
- 10.1016/j.jconrel.2011.07.018 · DOI
- 10.1182/blood-2012-12-474098 · DOI
- 10.1038/s41591-019-0498-z · DOI · Paper page
- 10.1002/smll.202304014 · DOI
- 10.1039/C8NR07146B · DOI
- 10.1007/s10118-021-2547-6 · DOI
- 10.3390/pharmaceutics15092214 · DOI
- 10.1007/s40820-020-00560-9 · DOI
- 10.1021/acsabm.0c01072 · DOI
- 10.3390/pharmaceutics13111892 · DOI
- 10.1016/j.actbio.2021.06.030 · DOI
- 10.1016/j.addr.2021.114085 · DOI
- 10.1080/03639045.2020.1820039 · DOI
- 10.1016/j.actbio.2021.06.030 · DOI
- 10.1016/j.colsurfa.2023.132504 · DOI
- 10.1038/nbt.3330 · DOI · Paper page
- 10.1146/annurev-pharmtox-010611-134623 · DOI
- 10.1016/j.apsb.2019.01.011 · DOI
- 10.1016/j.tcb.2023.01.002 · DOI · Paper page
- 10.1038/nrd2614 · DOI · Paper page
- 10.1021/acsami.6b12829 · DOI
- 10.1021/acsami.9b11877 · DOI
- 10.1021/acsami.0c05763 · DOI
- 10.1186/s12951-021-00922-4 · DOI
- 10.1038/s41586-019-1456-0 · DOI
- 10.1021/acsami.9b14084 · DOI
- 10.1186/s12951-020-00738-8 · DOI
- 10.1080/10717544.2020.1748758 · DOI · Paper page
- 10.7150/thno.52570 · DOI · Paper page
- 10.1016/j.jconrel.2015.09.031 · DOI · Paper page
- 10.1007/s11095-014-1593-y · DOI
- 10.1016/j.ymthe.2018.05.024 · DOI · Paper page
- 10.1182/blood-2020-138723 · DOI
- 10.3389/fonc.2022.822805 · DOI
- 10.1126/scitranslmed.abb6981 · DOI · Paper page
- 10.1016/j.phrs.2016.03.002 · DOI
- 10.1186/s40591-016-0048-8 · DOI
- 10.1016/j.jconrel.2011.02.010 · DOI
- 10.1016/j.addr.2015.12.007 · DOI
- 10.1016/j.addr.2015.11.013 · DOI
- 10.1016/j.jconrel.2012.04.036 · DOI
- 10.1002/pat.4676 · DOI
- 10.2217/nnm-2020-0090 · DOI
- 10.1016/j.ijpharm.2021.120397 · DOI
- 10.1021/nn403973g · DOI
- 10.1016/j.nano.2015.02.022 · DOI
- 10.1021/acs.bioconjchem.8b00404 · DOI
- 10.3324/haematol.2018.211490 · DOI
- 10.1038/nnano.2012.237 · DOI · Paper page
- 10.1021/acs.accounts.1c00267 · DOI
- 10.1002/agt2.120 · DOI
- 10.2217/nnm-2018-0122 · DOI
- 10.1073/pnas.1621240114 · DOI
- 10.1038/ncomms15144 · DOI
- 10.1111/j.2042-7158.2012.01567.x · DOI
- 10.1021/nn3022662 · DOI
- 10.1007/s12274-015-0841-8 · DOI
- 10.1021/ja4094617 · DOI
- 10.1038/srep10099 · DOI
- 10.1016/j.cej.2020.127258 · DOI
- 10.7150/thno.45803 · DOI
- 10.1016/j.jconrel.2022.12.048 · DOI
- 10.1039/C9TB01610D · DOI
- 10.2147/IJN.S115428 · DOI
- 10.1021/acsnano.9b00972 · DOI
- 10.1002/adma.202106390 · DOI
- 10.1038/nrc.2016.108 · DOI · Paper page
- 10.1021/accountsmr.2c00072 · DOI
- 10.1111/nyas.12403 · DOI
- 10.1136/ard.2004.030759 · DOI
- 10.1016/j.biopha.2016.03.004 · DOI
- 10.1021/mp300539f · DOI
- 10.1021/acs.nanolett.8b01236 · DOI
- 10.1002/adma.201801651 · DOI
- 10.1038/s41578-021-00315-x · DOI
Cited by
Sorted by citations
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
Metadata
- Authors
- Li, X., Zhang, Y., Wang, C., Wang, L., Ye, Y., Xue, R., Shi, Y., Su, Q., Zhu, Y., & Wang, L.
- Venue
- ACS Biomaterials Science & Engineering
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-01-31
- Volume
- 10
- Issue
- 2
- Pages
- 723-742
- ISSN
- 2373-9878
- Cited by
- 4
- References
- 3
- Language
- en
- Licence
- Funders
- Medical and Health Science and Technology Development Project of Shandong Province (2019WS132)
- Xuzhou Medical University (XYFZ202220, XYFZ202203)
- Science and Technology Development Plan of Shandong Province (M-2023051)
- Natural Science Foundation of Shandong Province (ZR2022MH058)
- Natural Science Foundation of Zhejiang Province (LZ22H030003)
- Linyi key Research Project (2022YX0011)
- Linyi key research and development plan (2022YX0052)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review